NDAINJECTIONINJECTABLE
Approved
Feb 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
TRAVAMULSION 10% (soybean oil) by Baxter is patients, providing macronutrients (amino acids, dextrose and lipids) and micronutrients (electrolytes) parenterally. Approved for total parenteral nutrition-induced cholestasis. First approved in 1982.
Drug data last refreshed 1w ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRAVAMULSION 10% is a soybean oil-based intravenous lipid emulsion approved in 1982 for Total Parenteral Nutrition (TPN)-induced cholestasis. It delivers macronutrients (amino acids, dextrose, lipids) and micronutrients (electrolytes) parenterally to patients unable to consume food orally. The lipids provide essential fatty acids and energy via beta-oxidation, while supporting membrane structure and gene regulation.
LOE Approaching
As a mature, LOE-approaching product with moderate competitive pressure (30), the brand team is likely in defensive mode with focus on market retention and cost management rather than growth initiatives.
Mechanism of Action
patients, providing macronutrients (amino acids, dextrose and lipids) and micronutrients (electrolytes) parenterally. The amino acids provide the structural units that make up proteins and are used to synthesize proteins and other biomolecules or are oxidized to urea and carbon dioxide as a source…
Indications (1)
Clinical Trials (3)
Soybean Oil Trial of cArdiovascular Risk
Started Mar 2015
60 enrolled
Cardiovascular DiseaseDiabetesMetabolic Syndrome
Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN
Started Nov 2008
100 enrolled
Parenteral Nutrition
Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers
Started Jun 2008
12 enrolled
Diseases, MetabolicInsulin Sensitivity
Worked on TRAVAMULSION 10% at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.